Skip to content

EB Pharma Developments

Active Private limited companyfounded 2022active for 4 yearsAlkerstraat 28, 3570 AlkenKBO/BCE: BE 0780.755.671

Annual accounts 2025

abbreviated format, filed on 25-03-2026, 128 days before the deadline
-€1,127
▼ €4,876
-€1,589
▼ €4,889
-€1,347
▼ €4,913
€5,298
▼ 68.2%
31.3%
▼ 56.1 percentage points
1.45
▼ 6.42

The abbreviated and micro formats do not require turnover, and these accounts state none. Without turnover there is no EBIT margin either.

Balance sheet

balance sheet total €16,951 on 31-12-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

31.3%

Higher than 39% of the 734 companies filing abbreviated accounts in other professional activities (NACE 74) in 2025.

1.45

Higher than 43% of the 710 companies filing abbreviated accounts in other professional activities (NACE 74) in 2025.

-7.9%

Higher than 17% of the 715 companies filing abbreviated accounts in other professional activities (NACE 74) in 2025.

EB Pharma Developments Middle half of the sector 80% of the sector Abbreviated accounts in other professional activities (NACE 74)

Net result: middle half · Equity: bottom quarter · Balance sheet total: bottom quarter · Working capital: middle half

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend202520242023202211 months
-8834,919-7,782-
5,29816,64513,07817,722
31.3%87.3%100.0%80.4%
1.457.88-5.11
2.200.150.000.24
-25.4%21.4%-35.5%91.5%
-7.9%18.7%-35.5%73.6%

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend202520242023202211 months
Balance sheet: assets
20/58 16,95119,06413,07822,037
29/58 16,95119,06413,07822,037
40/41 8,2159,4458,3789,555
40 03,880823-
41 8,2155,5657,5559,555
54/58 8,7369,6194,70012,482
Balance sheet: equity and liabilities
10/49 16,95119,06413,07822,037
10/15 5,29816,64513,07817,722
10/11 1,5001,5001,5001,500
13 3,79815,14511,57816,222
133 3,79815,14511,57816,222
14 0---
17/49 11,6542,42004,316
42/48 11,6542,42004,316
44 6361,920--
440/4 6361,920--
45 --04,316
450/3 --04,316
47/48 11,018500--
Income statement
9900 -1,1273,749-4,29720,964
640/8 462449446348
9901 -1,5893,300-4,74420,616
75/76B 3641,675196-
75 3641,675196-
65/66B 1231,4089779
65 1231,4089779
9903 -1,3473,567-4,64420,537
67/77 --04,316
9904 -1,3473,567-4,64416,222
9905 -1,3473,567-4,64416,222
Appropriation of the result
9906 -1,3473,567-4,64416,222
791/2 11,34704,644-
691/2 03,567016,222
6921 03,567016,222
694/7 10,000---
694 10,000---
Document PDFPDFPDFPDF

The full notes are in the filed accounts (PDF).

Source: Annual accounts 2025 (PDF), filed on 25-03-2026.

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
31-12-2025 abbreviated format 25-03-2026 2026-00062503 PDF
31-12-2024 abbreviated format 25-07-2025 2025-00307986 PDF
31-12-2023 abbreviated format 30-07-2024 2024-00315853 PDF
31-12-2022 micro format 22-08-2023 2023-00341411 PDF

Insights on EB Pharma Developments

The operating result for 2025 is a loss of €1,589, after a profit of €3,300 in 2024.

Debt's share of the balance-sheet total rises from 12.7% to 68.7%. Equity is lower and debt is higher.

Next steps